Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.61 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.61 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | IL1B | P01584 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HPGDS | O60760 | 2/20 | 0.50 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24123319 | 0.94 | CRBN (0.59) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL31461798 | 0.94 | CRBN (0.59) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21997031 | 0.91 | CRBN (0.59) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL25813908 | 0.91 | DDB1 (0.62) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL23302153 | 0.90 | CRBN (0.59) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL31255375 | 0.90 | CRBN (0.58) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL23300940 | 0.89 | CRBN (0.62) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL25166744 | 0.89 | CRBN (0.57) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL31586744 | 0.89 | CRBN (0.57) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL30044391 | 0.89 | CRBN (0.57) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| WO-2023115150-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| EP-4146660-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| CN-115605488-A | Bifunctional degradants of hematopoietic progenitor kinases and therapeutic uses thereof | 新锐思生物制药股份有限公司（US） | 2023-01-13 | — | — | CN | disclosed |
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |
| CN-114728936-A | Bifunctional compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021255213-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF BRAF | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021083949-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| US-20200361930-A1 | BIFUNCTIONAL MOLECULES THAT DEGRADE EGFR | HOFFMANN-LA ROCHE INC. (US) | 2020-11-19 | — | — | US | disclosed |
| US-20200361930-A1 | BIFUNCTIONAL MOLECULES THAT DEGRADE EGFR | HOFFMANN-LA ROCHE INC. (US) | 2020-11-19 | — | — | US | disclosed |
| WO-2019149922-A1 | COMPOUNDS WHICH CAUSE DEGRADATION OF EGFR, FOR USE AGAINST CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361930-A1 | BIFUNCTIONAL MOLECULES THAT DEGRADE EGFR | EGFR, ERBB2, MDM2 | CRBN 158/4885DDB1 328/4885IKZF3 841/4885 |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | CRBN 4327/4885DDB1 3430/4885IKZF3 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.